Abstract | BACKGROUND: METHODS: RESULTS: The sample was of 16 patients, who achieved at least a hematologic response; 10 were males (62.5%). The age range was 24 to 75 years. Two patients received nilotinib due to intolerance to imatinib; seven due to resistance to imatinib and seven due to lack of response. There was response in the two patients who received nilotinib due to intolerance. One patient died five months after starting nilotinib due to progression of leukemia; four patients achieved major molecular response, two patients had reduced expression of BCR-ABL gene. Six patients continued with high expression of BCR-ABL gene; two of them carrying M244V mutation, and one with a complex karyotype with numerical and structural alterations. CONCLUSIONS:
|
Authors | Enrique Báez-de la Fuente, Baltazar Arellano-Severiano |
Journal | Revista medica del Instituto Mexicano del Seguro Social
(Rev Med Inst Mex Seguro Soc)
2014 May-Jun
Vol. 52
Issue 3
Pg. 330-3
ISSN: 2448-5667 [Electronic] Mexico |
Vernacular Title | Nilotinib en pacientes con leucemia mieloide crónica con falla a imatinib. |
PMID | 24878095
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- Piperazines
- Pyrimidines
- Imatinib Mesylate
- nilotinib
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Benzamides
(therapeutic use)
- Female
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy)
- Male
- Middle Aged
- Piperazines
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Treatment Failure
- Young Adult
|